Literature DB >> 21609719

p90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: a pathogenic mechanism for ischemia-reperfusion injury.

Xi Shi1, Chen Yan, Sergiy M Nadtochiy, Jun-Ichi Abe, Paul S Brookes, Bradford C Berk.   

Abstract

Increasing evidence suggests that local renin-angiotensin system (RAS) plays an important role in cardiac diseases. Elevated p90 ribosomal S6 kinase (RSK) activity has been observed in diabetic animal, as well as in human failing hearts. We hypothesize that RSK mediates cardiac dysfunction by up regulating local RAS signaling. In the present study, we show that the prorenin mRNA level was significantly increased (~5.6-fold) in transgenic mouse hearts with cardiac specific expression of RSK (RSK-Tg). The RSK-Tg mice were more vulnerable to ischemia/reperfusion (I/R) injury than non-transgenic littermate controls (NLC). To further understand the direct contribution of cardiac renin to I/R injury, we used a Langendorff system to evaluate the effect of renin inhibition by aliskiren in RSK-Tg mouse hearts. In the vehicle-perfused group, I/R significantly decreased left ventricular developed pressure (LVDP) in RSK-Tg hearts compared to NLC (7% versus 60% of the baseline). However, aliskiren perfusion significantly increased LVDP in RSK-Tg (7% to 61%, p<0.01) but not in NLC hearts (60% to 62%, n.s.). The protective effect of aliskiren in RSK-Tg hearts was further demonstrated with positive (contraction) dp/dt (6.5% to 63%, p<0.01) and rate pressure product (RPP) (5% to 51%, p<0.01). Moreover, aliskiren significantly decreased I/R induced infarction in RSK-Tg (60% to 32%, p<0.01), compared to NLC hearts (37% to 32%, n.s.). These results suggest that RSK plays a crucial role in regulating local cardiac renin, which contributes to I/R induced cardiac injury and dysfunction. Thus, renin inhibition may provide an alternative therapeutic strategy under conditions of increased RAS.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609719      PMCID: PMC3124613          DOI: 10.1016/j.yjmcc.2011.05.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  14 in total

1.  Expression of renin and angiotensin-converting enzyme in human hearts.

Authors:  Y Endo-Mochizuki; N Mochizuki; H Sawa; A Takada; H Okamoto; H Kawaguchi; K Nagashima; A Kitabatake
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

2.  Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions.

Authors:  J P van Kats; A H Danser; J R van Meegen; L M Sassen; P D Verdouw; M A Schalekamp
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

3.  Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy.

Authors:  Yasuchika Takeishi; Qunhua Huang; Jun-ichi Abe; Wenyi Che; Jiing-Dwan Lee; Hisaaki Kawakatsu; Brian D Hoit; Bradford C Berk; Richard A Walsh
Journal:  Cardiovasc Res       Date:  2002-01       Impact factor: 10.787

4.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

5.  Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury.

Authors:  Naoya Maekawa; Jun-ichi Abe; Tetsuro Shishido; Seigo Itoh; Bo Ding; Virendra K Sharma; Shey-Shing Sheu; Burns C Blaxall; Bradford C Berk
Journal:  Circulation       Date:  2006-05-22       Impact factor: 29.690

6.  Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.

Authors:  O Zolk; M Flesch; P Schnabel; A C Teisman; Y M Pinto; W H van Gilst; M Paul; M Böhm
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

7.  Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium.

Authors:  Seigo Itoh; Bo Ding; Tetsuro Shishido; Nicole Lerner-Marmarosh; Nadan Wang; Naoya Maekawa; Bradford C Berk; Yasuchika Takeishi; Chen Yan; Burns C Blaxall; Jun-ichi Abe
Journal:  Circulation       Date:  2006-04-03       Impact factor: 29.690

8.  Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure.

Authors:  Dirk Westermann; Alexander Riad; Olga Lettau; Anton Roks; Konstantinos Savvatis; Peter Moritz Becher; Felicitas Escher; A H Jan Danser; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Hypertension       Date:  2008-10-27       Impact factor: 10.190

9.  Aliskiren.

Authors:  Morris J Brown
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

10.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

View more
  4 in total

1.  The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury.

Authors:  Xi Shi; Margaret M O'Neill; Scott MacDonnell; Paul S Brookes; Chen Yan; Bradford C Berk
Journal:  J Cardiovasc Pharmacol Ther       Date:  2015-06-30       Impact factor: 2.457

2.  Angiotensin II and ischemic preconditioning synergize to improve mitochondrial function while showing additive effects on ventricular postischemic recovery.

Authors:  Rebeca E Nuñez; Miriam Castro; Sabzali Javadov; Nelson Escobales
Journal:  J Cardiovasc Pharmacol       Date:  2014-08       Impact factor: 3.105

3.  p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction.

Authors:  Nhat-Tu Le; Yuichiro Takei; Tetsuro Shishido; Chang-Hoon Woo; Eugene Chang; Kyung-Sun Heo; Hakjoo Lee; Yan Lu; Craig Morrell; Masayoshi Oikawa; Carolyn McClain; Xin Wang; Cathy Tournier; Carlos A Molina; Jack Taunton; Chen Yan; Keigi Fujiwara; Cam Patterson; Jay Yang; Jun-ichi Abe
Journal:  Circ Res       Date:  2012-01-19       Impact factor: 17.367

4.  Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2).

Authors:  Darkhan Utepbergenov; Paulina M Hennig; Urszula Derewenda; Mykhaylo V Artamonov; Avril V Somlyo; Zygmunt S Derewenda
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.